دورية أكاديمية
RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial
| العنوان: | RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial |
|---|---|
| المؤلفون: | Daniel Martin, Panagiotis Balermpas, Johannes Gollrad, Christian Weiß, Chiara Valentini, Martin Stuschke, Henning Schäfer, Christoph Henkenberens, Jürgen Debus, David Krug, Thomas Kuhnt, Thomas Brunner, Tilman Bostel, Rita Engenhart-Cabillic, Ursula Nestle, Stephanie E. Combs, Claus Belka, Matthias Hautmann, Guido Hildebrandt, Cihan Gani, Bülent Polat, Claus Rödel, Emmanouil Fokas |
| المصدر: | Clinical and Translational Radiation Oncology, Vol 23, Iss , Pp 43-49 (2020) |
| بيانات النشر: | Elsevier, 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Anal cancer, Durvalumab, Immunotherapy, Radiochemotherapy, Phase 2, Disease-free survival, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Purpose: Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy with RCT in patients with ASCC due to its association with human papilloma virus (HPV) infection. Methods/design: RADIANCE is an investigator initiated, prospective, multicenter, randomized phase II trial testing the addition of Durvalumab, a PD-L1 immune checkpoint inhibitor, to standard RCT in 178 patients with locally advanced ASCC (T2 ≥ 4 cm Nany, cT3-4 and/or cN+). In the control arm, patients will be treated with standard mitomycin C (MMC)/5-fluorouracil (5-FU)-based RCT. Intensity-modulated radiotherapy (IMRT) will be applied as follows: PTV_A (primary tumor) T1-T2 |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2405-6308 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2405630820300343; https://doaj.org/toc/2405-6308 |
| DOI: | 10.1016/j.ctro.2020.04.010 |
| URL الوصول: | https://doaj.org/article/d3e4ec6562624439855c9fd77d25efb9 |
| رقم الأكسشن: | edsdoj.3e4ec6562624439855c9fd77d25efb9 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24056308 |
|---|---|
| DOI: | 10.1016/j.ctro.2020.04.010 |